Table 1 Sociodemographic and clinical characteristics of the study population, stratified by case and control groups
From: Bacterial infection in patients with juvenile systemic lupus erythematosus and fever
Characteristic | Total (n, %) | Confirmed Bacterial Infection (Cases n = 20) | No Bacterial Confirmation (Controls n = 96) |
|---|---|---|---|
Sex: male | 16 (13%) | 2 (10%) | 14 (15%) |
Sex female | 100 (86%) | 18 (90%) | 82 (85%) |
Origin: Cali | 70 (60%) | 11 (55%) | 59 (61%) |
Social Security | |||
Contributive | 37 (32%) | 6 (30%) | 31 (32%) |
Subsidized | 78 (67%) | 14 (70%) | 64 (67%) |
Special | 1 | 0 | 1 |
Exception | 0 | 0 | 0 |
Uninsured | 0 | 0 | 0 |
Main Complaint Symptom | |||
Respiratory | 11 (9%) | 2 (10%) | 9 (9%) |
Gastrointestinal | 14 (12%) | 2 (10%) | 12 (13%) |
Urinary | 2 (2%) | 0 | 2 (2%) |
Systemics | 32 (28%) | 4 (20%) | 28 (29%) |
Musculoskeletal | 25 (22%) | 4 (20%) | 21 (22%) |
Skin, Soft Tissues, Neurological | 5 (4%) | 1 (5%) | 4 (4%) |
6 (5%) | 0 | 6 (6%) | |
Fever | 2 (2%) | 0 | 2 (2%) |
Hematological | 19 (16%) | 7 (35%) | 12 (13%) |
Use of Immunomodulators | 63 (54%) | 16 (80%) | 47 (49%) |
Type of Immunomodulator | |||
Steroid alone | 7 (6%) | 1 (5%) | 6 (6%) |
Azathioprine | 3 (3%) | 0 | 3 (3%) |
Methotrexate | 1 (1%) | 0 | 1 (1%) |
Mycophenolate | 2 (2%) | 0 | 2 (2%) |
Cyclophosphamide | 1 (1%) | 0 | 1 (1%) |
Biologics | 1 (1%) | 0 | 1 (1%) |
Combined Therapy | 52 (45%) | 14 (70%) | 38 (40%) |
High-dose Steroids | 24 (21%) | 6 (30%) | 18 (19%) |
SLE Onset | 28 (24%) | 2 (10%) | 26 (27%) |
Renal Replacement Therapy | 19 (16%) | 7 (35%) | 12 (13%) |
Nutritional Status | |||
Eutrophic | 60 (52%) | 9 (45%) | 51 (53%) |
Depleted | 43 (37%) | 6 (30%) | 37 (39%) |
Severe Malnutrition | 5 (4%) | 1 (5%) | 4 (4%) |
Obesity | 8 (7%) | 4 (20%) | 4 (4%) |